Virginia M-Y Lee
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (10)
Epigenetic mechanisms, including histone acetylation, regulate learning and memory and underlie Alzheimer’s disease and related dementia (ADRD). Acetyl-CoA synthetase 2 (ACSS2), an enzyme generating acetyl-CoA, locally regulates histone acetylation and gene expression in neuronal nuclei. This regulatory mechanism may be a promising target for therapeutic intervention in neurodegenerative diseases. Previously, we showed that systemic ACSS2 knockout mice, although largely normal in physiology, exhibit memory deficits. Here, we investigated whether increasing ACSS2 levels could protect neurons against disease and age-associated cognitive decline. Given the role of tau in ADRD, we used primary hippocampal neurons that mimic the sporadic development of tau pathology and the P301S transgenic mouse model for tau-induced memory decline. Our results show that ACSS2 upregulation mitigates tau-induced transcriptional alterations, enhances neuronal resilience against tau pathology, improves long-term potentiation, and ameliorates memory deficits. Additionally, boosting histone acetylation through ACSS2 countered age-related memory decline. These findings indicate that increasing ACSS2 is highly effective in countering age- and tau-induced transcriptome changes, preserving elevated levels of synaptic genes, and safeguarding synaptic integrity. These findings position ACSS2 as a key epigenetic regulator of cognitive aging and ADRD, highlighting its potential for targeted therapeutics to enhance brain resilience and function.
Year:
2026
Neuronal hyperexcitability is a hallmark of amyotrophic lateral sclerosis (ALS), but its relationship with the TDP-43 aggregates that comprise the predominant pathology in over 90% of ALS cases remains unclear. Emerging evidence indicates that TDP-43 pathology induces neuronal hyperexcitability, which may contribute to excitotoxic neuronal death. To characterize TDP-43 mediated network excitability changes in a disease-relevant model, we performed in vivo continuous electroencephalography monitoring and ex vivo acute hippocampal slice electrophysiology in rNLS8 mice (males and females), which express human TDP-43 with a defective nuclear localization signal (hTDP-43ΔNLS). Surprisingly, we identified the presence of seizures in ∼64% of rNLS8 mice beginning ∼2.5 weeks after transgene induction (off-DOX). More broadly, we observed longitudinal changes in cortical EEG patterns and circuit hyperexcitability preceding neurodegeneration of vulnerable hippocampal subfields. Consistent with previous reports, we have observed broad dysregulation of AMPA subunit expression in mice expressing hTDP-43ΔNLS. These changes were most pronounced in the hippocampus, where we hypothesized they promote hyperexcitability and ultimately, excitotoxic cell death. Interestingly, hippocampal injection of AAV encoding inhibitory DREADDs (hM4Di) and daily activation with CNO ligand rescued anxiety deficits on the elevated zero maze but did not reduce neurodegeneration. Moreover, therapeutic doses of the antiseizure medications, valproic acid and levetiracetam, did not improve behavior or prevent neurodegeneration. These results highlight the complex relationship between TDP-43-mediated neuronal hyperexcitability and neurodegeneration. Although targeting hyperexcitability may ameliorate some behavioral deficits, our study suggests it may not be sufficient to halt or slow neurodegeneration in TDP-43-related proteinopathies.
Year:
2025
Cerebrospinal fluid (CSF) amyloid beta (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau181) are well accepted markers of Alzheimer’s disease. We performed a GWAS meta-analysis including 18,948 individuals of European and 416 non-European ancestry. We identified 12 genome-wide significant loci across all three biomarkers, eight of them novel. We replicated the association of CSF biomarkers with APOE , CR1 , GMNC/CCDC50 and C16orf95/MAP1LC3B . Novel loci included BIN1 for Aβ42 and GNA12, MS4A6A, SLCO1A2 with both t-tau and p-tau181, as well as additional loci on chr. 8, near ANGPT1 and chr. 9 near SMARCA2 . We also demonstrated that these variants were not only associated with CSF level of the three biomarkers but also showed significant association with AD risk, disease progression and/or brain amyloidosis. The associated genes are implicated in lipid metabolism independent APOE , as well as autophagy and brain volume regulation driven by t-tau and p-tau181 dysregulation.
Year:
2025
Structurally diverse tau filaments form proteinaceous aggregates in a heterogeneous group of neurodegenerative diseases called tauopathies 1 . The factors extrinsic to the highly ordered core structure that influence tau filament stability are not well understood. Here, we found that polyubiquitinated tau filaments from Alzheimer’s disease and vacuolar tauopathy human brain tissue exhibit distinct seeding patterns in mice, in association with differences in tau filament ultrastructure determined by cryo-electron microscopy. Interestingly, chemical modulation of the polarity of polyubiquitin adjacent to the tau core with the small molecule ubistatin B resulted in the repositioning of poorly structured densities towards positively charged residues on the highly structured core filament, leading to shifting of the protofilament-protofilament interface of certain vacuolar tauopathy tau filaments. These results suggest that the structure of tau filaments that are associated with different seeding activities in vivo can be influenced by post-translational modifications.
Year:
2025
Year:
2024
The transmission of tau pathology has been proposed as one of the major mechanisms for the spatiotemporal spreading of tau pathology in neurodegenerative diseases. Over the last decade, studies have demonstrated that targeting total or pathological tau using tau antibodies can mitigate the development of tau pathology in tauopathy or Alzheimer's disease (AD) mouse models, and multiple tau immunotherapy agents have progressed to clinical trials. Tau antibodies are believed to inhibit the internalization of pathologic seeds and/or block seed elongation after seed internalization. To further address the mechanism of tau antibody inhibition of pathological spread, we conducted immunotherapy studies in mouse primary neurons and wild-type mice (females) seeded with AD patient-derived tau to induce the formation and spreading of tau pathology. Notably, we evaluated the effect of a mouse tau-specific antibody (mTau8) which does not interact with AD–tau seeds in these models. Our results show that mTau8 crosses the blood–brain barrier at levels similar to other antibodies and effectively decreases AD–tau-seeded tau pathology in vitro and in vivo. Importantly, our data suggest that mTau8 binds to endogenous intraneuronal mouse tau, thereby inhibiting the elongation of internalized tau seeds. These findings provide valuable insights into the possible mechanism underlying antibody-based therapies for treating tauopathies.
Year:
2024
Aggregation of misfolded alpha-synuclein (aSyn) within the brain is the pathologic hallmark of Lewy body diseases (LBD), including Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). Evidence exists for aSyn “strains” – conformations with distinct biological properties. However, biomarkers for PD vs. DLB, including potential aSyn strain differences, are lacking. Here, we used two monoclonal antibodies selective for different in vitro aSyn species – termed Strain A and B – to evaluate human brain tissue, cerebrospinal fluid (CSF), and plasma. Surprisingly, levels of Strain A and B aSyn species differed in plasma from individuals with PD vs. DLB in two independent cohorts. Lower plasma aSyn Strain A species also predicted subsequent PD cognitive decline. Strain A and Strain B aSyn species were undetectable in CSF, but plasma aSyn species could template aSyn fibrillization, particularly in PD. Our findings suggest that aSyn strains may impact LBD clinical presentation and originate outside the brain.
Year:
2024
To elucidate the molecular basis of multiple system atrophy (MSA), a neurodegenerative disease, we conducted a genome-wide association study (GWAS) in a Japanese MSA case/control series followed by replication studies in Japanese, Korean, Chinese, European, and North American samples. In the GWAS stage, rs2303744 on chromosome 19 showed a suggestive association ( P = 6.5 × 10 − 7 ) that was replicated in additional Japanese samples ( P = 2.9 × 10 − 6 , odds ratio (OR) = 1.58; 95% confidence interval (CI), 1.30–1.91), and then confirmed as highly significant in a meta-analysis of East Asian population data ( P = 5.0 × 10 − 15 , OR = 1.49; 95% CI 1.35–1.65). The association of rs2303744 with MSA remained significant in combined European/North American samples ( P = 0.017, OR = 1.12; 95% CI 1.02–1.23) despite allele frequencies being quite different between these populations. rs2303744 leads to an amino acid substitution in PLA2G4C that encodes the cPLA2γ lysophospholipase/transacylase. The cPLA2γ-Ile143 isoform encoded by the MSA risk allele has significantly decreased transacylase activity compared with the alternate cPLA2γ-Val143 isoform, and may perturb membrane phospholipids and promote oligodendroglial pathology.
Year:
2024
Year:
2023
Year:
2023
Collaborators (67)
Alice S. Chen‐Plotkin
Sponsor
University of Pennsylvania
Stefanie Heilmann-Heimbach
Head of Laboratory, Research Group Leader
University Hospital Bonn
Maria Jesús Bullido Gómez-Heras
Researcher
Universidad Autónoma de Madrid
Pau Pastor
Institut Català de la Salut
Eloy Rodriguez-Rodríguez
Instituto de Investigación Marqués de Valdecilla
Edward B Lee
PI
University of Pennsylvania Perelman School of Medicine
Henrik Zetterberg
Professor
University of Gothenburg
Shelley L. Berger
Director
University of Pennsylvania
Agustín Ruiz Laza
Director of the Biology Core
University of Texas Health Science Center at San Antonio
Harro Seelaar
Neurologist
Erasmus MC
Sonja Scholz
National Institute of Neurological Disorders and Stroke
Johannes Kornhuber
-
Thomas F. Tropea
-
Henne Holstege
Professor
KU Leuven
Markus Nöthen
Professor, Director
University Hospital Bonn
Suzanne Schindler
Associate Professor
Washington University in St. Louis
Pieter Jelle Visser
Karolinska Institutet
Jordi Pérez-Tur
Coordinador Adjunto al Área Global Vida
Agencia Estatal Consejo Superior de Investigaciones Científicas
Ken Yamamoto
Professor
Kurume University
Jean-Charles Lambert
Head of research unit
INSERM
Kelvin Luk
Associate Professor
University of Pennsylvania
Betty Tijms
Senior researcher
VU medisch centrum
Simon Laws
Professor
Edith Cowan University
Henry Houlden
Professor of Neurogenetics
-
David Irwin
Assistant Professor
University of Pennsylvania
Jonathan Vogelgsang
Harvard University
Ciyang Wang
Washington University in St. Louis
Daniel Weintraub
Professor, Clinician-Educator
University of Pennsylvania
Timothy Hohman
Professor
Vanderbilt University Medical Center
Pablo Mir
-
Tatiana Foroud
Department Chair
Indiana University
Norbert Scherbaum
Professor for Clinical Addiction Research
University of Duisburg-Essen Faculty of Medizin
Ullrich Wüllner
University of Bonn
Margda Waern
University of Gothenburg
Nancy M. Bonini
PI
University of Pennsylvania
Osamu Onodera
Professor
Niigata University
Muhammad Ali
Assistant Professor
Washington University in St. Louis
Tatsushi Toda
University of Tokyo
Andrew Saykin
Professor and Director, Center for Neuroimaging and Indiana Alzheimer's Disease Research Center
Indiana University School of Medicine
Sami Heikkinen
Research Director
University of Eastern Finland
Wiesje van der Flier
Scientific director
VU medisch centrum
John Dani
Chair, Director, Professor
University of Pennsylvania Perelman School of Medicine
David M. Holtzman
Washington University School of Medicine
Dan Rujescu
Head of Clinical Division of General Psychiatry
Medical University of Vienna
Yi-Wei Chang
Associate Professor
University of Pennsylvania
Robert Perneczky
Professor
Ludwig-Maximilians-Universität München
Gen Sobue
Nagoya University
Martin Ingelsson
Specialist
Uppsala University Hospital
Hilkka Soininen
Kuopio University Hospital
Shoji Tsuji
Professor
International University of Health and Welfare
George Burslem
Assistant Professor
University of Pennsylvania
Norihito Uemura
Senior Lecturer
Kyoto University
Emil Gustavsson
Assistant Research Professor
University of Cambridge
Riccardo E Marioni
University of Edinburgh
Alison Goate
Professor and Chair
Icahn School of Medicine at Mount Sinai
Alfredo Ramirez
University of Texas Health Science Center at San Antonio
Masato Koike
Professor and Chairman
Juntendo University Graduate School of Medicine
Shinichi Morishita
Project Professor
University of Tokyo
Carlos Cruchaga
Professor
Washington University in St. Louis
Ville Leinonen
Professor
University of Eastern Finland
Lutz Froelich
Head
Zentralinstitut für Seelische Gesundheit
Rebecca Sims
Senior Research Fellow
Cardiff University
Lars Bertram
Professor of Genome Analytics
University of Lübeck
Cornelia Van Duijn
Professor
University of Oxford
Alberto Lleó
Director
Hospital de la Santa Creu i Sant Pau
Sterling Johnson
Professor
University of Wisconsin-Madison
Menghan Liu
Washington University in St. Louis
Make your next move.
Prepare your application
Review drafts before you send them.